Rc. Chan et al., Anti-restenotic effect of copper-62 liquid-filled balloon in porcine coronary arteries: Novel use of a short half-life positron emitter, INT J RAD O, 48(2), 2000, pp. 583-592
Citations number
42
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Purpose: To determine the efficacy of the use of copper-62, a positron emit
ter with a half-life of 9.7 minutes, as an intracoronary brachytherapy (IRB
T) source in the prevention of neointima formation (NF) following overstret
ch balloon injury (BI) in the porcine model.
Methods and Materials: Sixteen swine were treated after BI to their left an
terior descending (LAD), left circumflex (LCX), and/or right coronary arter
y (RCA), Twelve of the injured arteries received placebo and 10 received 25
Gy, delivered to 0.5 mm from the surface of the treatment balloon filled w
ith liquid Cu-62. Dosimetry was based on Monte Carlo calculations. Two week
s after treatment, the animals were sacrificed, and the treated coronaries
were perfusion-fixed and stained. Intimal area (IA) and medial fracture len
gth (FL) were analyzed by computer-aided histomorphometry.
Results: The (Zn-62/Cu-62) generator, together with a rapid concentration p
rocess, was successful in delivering the short-lived Cu-62 at the high conc
entration required for intravascular brachytherapy (IVBT), The fracture len
gth in the two groups was similar (2.10 +/- 0.57; 2.02 +/- 0.77; g = NS). A
rteries studied showed significant reduction in NF (IA: 0.23 +/- 0.47 mm(2)
vs. 1.08 +/- 0.57 mm(2); p < 0.01. IA/FL = 0.09 +/- 0.17 mm vs. 0.51 +/- 0
.21 mm; p < 0.01).
Conclusions: This study demonstrated that use of liquid Cu-62 as an IVBT so
urce is safe and feasible. All 16 swine tolerated the treatment well with n
o radiation-induced side effects or symptoms throughout the 2-week period,
The isotope delivered the dose necessary to inhibit NF in the porcine coron
ary BI model. (C) 2000 Elsevier Science Inc.